Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Lymphoma | Case report

Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature

Authors: Mengwei Ren, Yanli Liu

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

Primary lymphoma of the prostate is an exceedingly rare disease, with diffuse large B-cell lymphoma being the most common known subtype in a small number of reported cases. Due to its low prevalence, there has been a chronic lack of targeted diagnostic guidelines and treatment procedures.

Case presentation

In this article, we report a case of primary diffuse large B-cell lymphoma of the prostate in a 70-year-old Asian man who presented with symptoms of urinary tract obstruction. Histological and immunocytochemical studies of transurethral biopsy of the prostate showed diffuse large B-cell lymphoma. The patient was managed by a combination of eight courses of chemotherapy with a regimen including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and radiotherapy. Post-chemotherapy computed tomography scans showed complete remission. He remained disease free, until now, 15 months after the end of therapy. We also reviewed and analyzed relevant literature to illustrate the diagnosis, treatment, and prognosis of this disease.

Conclusion

Diffuse large B-cell non-Hodgkin’s lymphoma originating in the prostate is a rare and highly aggressive disease that lacks specificity in its clinical presentation and is easily misdiagnosed. This disease should be considered clinically in patients with significant prostate enlargement and insignificant prostate-specific antigen elevation. The diagnosis can be clarified with a prostate puncture biopsy. Chemotherapy is the main treatment for patients and may be supplemented with surgical treatment and radiotherapy.
Literature
1.
go back to reference Sarris A, Dimopoulos M, Pugh W, et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol. 1995;153:1852–4.CrossRef Sarris A, Dimopoulos M, Pugh W, et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol. 1995;153:1852–4.CrossRef
2.
go back to reference Wright DH. Pathology of extra-nodal non Hodgkin lymphomas. Clin Oncol (R Coll Radiol). 2012;24:319–28.CrossRef Wright DH. Pathology of extra-nodal non Hodgkin lymphomas. Clin Oncol (R Coll Radiol). 2012;24:319–28.CrossRef
3.
go back to reference Zhou XD, Qi RX, Feng X, et al. Clinicopathological characterization of non-Hodgkin lymphoma of the prostate. Zhonghua Nan Ke Xue. 2019;25:340–5.PubMed Zhou XD, Qi RX, Feng X, et al. Clinicopathological characterization of non-Hodgkin lymphoma of the prostate. Zhonghua Nan Ke Xue. 2019;25:340–5.PubMed
4.
go back to reference Bostwick DG, Iczkowski KA, Amin MB, et al. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83:732–8.CrossRef Bostwick DG, Iczkowski KA, Amin MB, et al. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83:732–8.CrossRef
6.
go back to reference Ezekwudo DE, Ogunleye F, Gbadamosi B, et al. Primary extranodal diffuse large B-cell lymphoma of the prostate: a case report. Case Rep Oncol. 2017;10:199–204.CrossRef Ezekwudo DE, Ogunleye F, Gbadamosi B, et al. Primary extranodal diffuse large B-cell lymphoma of the prostate: a case report. Case Rep Oncol. 2017;10:199–204.CrossRef
7.
go back to reference Fang T. Clinical analysis of 29 cases with primary malignant lymphoma of the prostate. Chin J Clin Oncol. 2007;4:129–32.CrossRef Fang T. Clinical analysis of 29 cases with primary malignant lymphoma of the prostate. Chin J Clin Oncol. 2007;4:129–32.CrossRef
8.
go back to reference Whitmore WF, Skarin AT, Rosenthal DS. Urological presentations of non-Hodgkin’s lymphomas. J Urol. 1982;128:953–6.CrossRef Whitmore WF, Skarin AT, Rosenthal DS. Urological presentations of non-Hodgkin’s lymphomas. J Urol. 1982;128:953–6.CrossRef
9.
go back to reference Fukutani K, Koyama Y, Fujimori M, et al. Primary malignant lymphoma of the prostate: report of a case achieving complete response to combination chemotherapy and review of 22 Japanese cases. Nihon Hinyokika Gakkai zasshi. 2003;94:621–5.PubMed Fukutani K, Koyama Y, Fujimori M, et al. Primary malignant lymphoma of the prostate: report of a case achieving complete response to combination chemotherapy and review of 22 Japanese cases. Nihon Hinyokika Gakkai zasshi. 2003;94:621–5.PubMed
10.
go back to reference Wang N, Tian-Qiang YU, Jia HE, et al. Primary lymphoma of the prostate: one case report and literature review. Chin Gen Pract. 2017;29(v.20;No.548):119–21. Wang N, Tian-Qiang YU, Jia HE, et al. Primary lymphoma of the prostate: one case report and literature review. Chin Gen Pract. 2017;29(v.20;No.548):119–21.
11.
go back to reference Alvarez CA, Rodriguez BI, Perez LA. Primary diffuse large B-cell lymphoma of the prostate in a young patient. Int Braz J Urol. 2006;32:64–5.CrossRef Alvarez CA, Rodriguez BI, Perez LA. Primary diffuse large B-cell lymphoma of the prostate in a young patient. Int Braz J Urol. 2006;32:64–5.CrossRef
12.
go back to reference Jafari A, Mofid B, Tabibi A, Kowsari F. Primary prostate lymphoma managed with combined modality treatment: a case report. Urol J. 2019;16:412–4.PubMed Jafari A, Mofid B, Tabibi A, Kowsari F. Primary prostate lymphoma managed with combined modality treatment: a case report. Urol J. 2019;16:412–4.PubMed
13.
go back to reference Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL001): a multicentre seamless design study. Lancet. 2020;396:839–52.CrossRef Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL001): a multicentre seamless design study. Lancet. 2020;396:839–52.CrossRef
14.
go back to reference Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155–65.CrossRef Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155–65.CrossRef
15.
go back to reference Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379:1711–21.CrossRef Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379:1711–21.CrossRef
16.
go back to reference Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.CrossRef Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.CrossRef
17.
go back to reference Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291–9.CrossRef Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291–9.CrossRef
18.
go back to reference Kerbl K, Pauer W. Primary non-Hodgkin lymphoma of prostate. Urology. 1988;32:347–9.CrossRef Kerbl K, Pauer W. Primary non-Hodgkin lymphoma of prostate. Urology. 1988;32:347–9.CrossRef
19.
go back to reference International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRef International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRef
Metadata
Title
Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature
Authors
Mengwei Ren
Yanli Liu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-03143-3

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue